Company Theranexus

Equities

ALTHX

FR0013286259

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Euronext Paris Other stock markets 07:49:05 2024-04-19 am EDT			5-day change	1st Jan Change
1.05 ^EUR	-0.47%		-6.14%	-4.46%

12:10pm	Theranexus: share price rises following promising trial results	CF
Mar. 11	Theranexus: CEO takes over as Chairman of the Board	CF

Theranexus is an innovative biopharmaceutical company that emerged from the French Atomic Energy Commission (CEA) and specializes in the treatment of neurological diseases and pioneer in the development of drug candidates targeting both neurons and glial cells.

Theranexus has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.

Number of employees: 19

Managers	Title	Age	Since
Mathieu Bernard Mari Charveriat CEO	Chief Executive Officer	-	13-03-18
Franck Joseph Mouthon FOU	Founder	-	13-03-18
Thierry Bertrand Lambert DFI	Director of Finance/CFO	-	16-12-31
Marie Sebille CTO	Chief Tech/Sci/R&D Officer	-	21-10-18
Francoise Vincent-Larrode HRO	Human Resources Officer	-	17-12-31
Julien Veys PRN	Corporate Officer/Principal	-	15-12-31

Members of the board	Title	Age	Since
Jérôme Martinez BRD	Director/Board Member	63	18-12-12
Sébastien Descarpentries BRD	Director/Board Member	50	17-09-25
Franck Joseph Mouthon FOU	Founder	-	13-03-18
Mathieu Bernard Mari Charveriat CEO	Chief Executive Officer	-	13-03-18
Rodolphe Besserve BRD	Director/Board Member	51	-
Eric Doulat BRD	Director/Board Member	-	19-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	5,346,213	4,220,699 ( 78.95 %)	0	78.95 %

Name	Equities	%	Valuation
DNCA Finance SA 2.537 %	196,859	2.537 %	244 924 €
ACA Asset Management Company & Associés SASU 0.2734 %	21,210	0.2734 %	26 389 €
NOVACAP Asset Management SA 0.1719 %	13,334	0.1719 %	16 590 €

Name	Equities	%	Valuation
NOVACAP Asset Management SA -	0	-	- €

Theranexus SA

Pépinière Laennec 60, avenue Rockefeller

69008, Lyon

+33 1 88 89 70 31

http://www.theranexus.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.055 EUR

Average target price

4 EUR

Spread / Average Target

+279.15%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
THERANEXUS	+0.89%	8.73M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-1.22%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-8.12%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs